Predicting chronic graft-versus-host disease and mortality risk with BIOPREVENT

In this episode, Sophie Paczesny explains that BIOPREVENT accurately predicts individual risk of future cGVHD and NRM using biomarkers at 3 months post-HCT. A publicly available R Shiny web application supports its clinical use. Further studies are needed to explore its role in guiding preemptive therapy.

Protective, subtype antibody family targets the active site of influenza A virus neuraminidase

In this video, Dr. Seth J. Zost presents an antibody lineage from a single donor that binds the active site of influenza neuraminidase, cross-reacts with antigenically diverse viruses, and protects mice from infection.

Capillary loss and fibrosis in experimental kidney disease is prevented with TIE2 activation

In this episode, Marie Jeansson explains how the paper's findings suggest that TIE2 activation via angiopoietin-2 (ANGPT2)-binding and TIE2-activating antibody warrants investigation as a therapy in human CKD, where there is a substantial unmet medical need.

STING-mediated antitumor immunity and CDK12/13 inactivation triggers

In this episode, Yi Bao explains the that the manuscript's findings establish STING activation as the key driver of T cell infiltration and the immune-hot tumor microenvironment in CDK12 mutant cancers, suggesting that dual CDK12/13 inhibitors and degraders activate anti-tumor immunity and potentiate responses to immunotherapies.

Spesolimab targets IL-36R to alleviate inflammation and reduce generalized pustular psoriasis flares

In this episode, James G. Kreuger explains that people with generalized pustular psoriasis experience underlying skin inflammation, even in the absence of flares. Spesolimab treatment helps control the inflammation and prevent future flares.